Roche has entered the antibody-targeted protein degrader space by expanding its C4 Therapeutics collaboration, committing $20 million upfront for two oncology targets and more than $1 billion in milestone payments. The deal underscores Big Pharma’s shift from antibody-drug conjugates toward next-generation modalities that combine target recognition with intracellular protein degradation. Roche’s partnership with C4 dates back roughly a decade, and the added funding suggests it is prioritizing a “degrader plus antibody” strategy for difficult-to-treat cancers. The structure also reflects how degrader platforms are moving beyond early science into commercially meaningful development programs. For investors and pipeline planners, the Roche-C4 move signals that degradation is no longer a standalone approach—pharma is pairing it with established antibody engineering capabilities to improve both selectivity and durability of response.